Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 28Lung Neoplasms 27Neoplasm Metastasis 26Carcinoma, Non-Small-Cell Lung 21Multiple Myeloma 18Urinary Bladder Neoplasms 16Breast Neoplasms 16Lymphoma 15Glioma 14Colorectal Neoplasms 14Pancreatic Neoplasms 13Lymphoma, Large B-Cell, Diffuse 13Carcinoma, Renal Cell 13Squamous Cell Carcinoma of Head and Neck 12Ovarian Neoplasms 12Melanoma 12Triple Negative Breast Neoplasms 11Glioblastoma 10Oropharyngeal Neoplasms 9Mouth Neoplasms 9Fallopian Tube Neoplasms 9Carcinoma 9Sarcoma 8Lymphoma, Non-Hodgkin 8Endometrial Neoplasms 8Carcinoma, Transitional Cell 8Medulloblastoma 7Lymphoma, Follicular 7Laryngeal Neoplasms 7Carcinoma, Hepatocellular 7

Interventions

pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1merphos 1durvalumab 1Vinblastine 1Specimen Handling 1Platinum 1Methotrexate 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Gemcitabine 1Doxorubicin 1Disulfides 1Cisplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Renal Pelvis and Ureter Urothelial Carcinoma × Magnetic Resonance Spectroscopy × 30 days × Clear all
NCT04628767 2026-06-03

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2/3 Recruiting
131 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡